25 May 2013
Keywords: Pfizer, Inlyta, Bosutinib, USA, FDA, Kidney cancer, Myeloid leukemia
Article | 30 January 2012
The US Food and Drug Administration on Friday approved global pharma behemoth Pfizer’s (NYSE: PFE) Inlyta (axitinib) to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 January 2012
24 May 2013
© 2013 thepharmaletter.com